Media Room

Here you can find news, a variety of media and other useful information on us

Featured articles

Ellipses In-Licences First in Class Novel Immuno-Oncology Agent

Ellipses In-Licences First in Class Novel Immuno-Oncology Agent With Potential as a Next Generation Checkpoint Inhibitor London, February 11, 2025: Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today it is to develop a next-generation immuno-oncology drug which could [...]

Read more

Ellipses Launches Clinical Trial Programme in Middle East

Ellipses Pharma Launches Pioneering Clinical Trial Programme in Middle East London, December 23, 2024: Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today it has inaugurated the first large-scale Phase 1/2 oncology clinical study of its kind in the [...]

Read more

Ellipses Pharma publishes the latest data from an ongoing Phase 1/2 clinical trial of EP0042

Ellipses Pharma publishes the latest data from an ongoing Phase 1/2 clinical trial of EP0042 at ASH 2024 London, UK, 9th December 2024: Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, has published the latest data from an ongoing Phase 1/2 clinical trial of EP0042, [...]

Read more

Rewriting Cancer produced for UICC by BBC Storyworks

Rewriting Cancer produced for UICC by BBC Storyworks We are proud to have been involved in the Rewriting Cancer series, produced for UICC by BBC StoryWorks in 2024. This series is separated into three parts: Changing the Odds, Changing the Outcome, and Changing the Experience. Aiming to dispel myths, highlight advancements in cancer diagnosis, prevention, [...]

Read more

Want to learn more?